Language selection

Government of Canada / Gouvernement du Canada

Search

Flame Retardants Group

Information sheet

These substances were identified for action under the Chemicals Management Plan (CMP). The screening assessment focuses on 10 substances referred to collectively under the CMP as the Flame Retardants Group.

Summary of publications
Substance group Subgroup CAS RN Common name and acronym DSL name Human health risk characterization document Risk management scope (updated human health component) Draft screening assessment Risk management scope Proposed conclusion on section 64 criteria Follow-up activities
Flame Retardants Group Alkyl organophosphate 78-40-0Table 1 Footnote b Triethylphosphate; Triethyl Phosphate (TEP) Phosphoric acid, triethyl ester None None HTML HTML Meets one or more of the criteria Refer to risk management scope
Alkyl organophosphate 78-42-2Table 1 Footnote b Tris(2-ethylhexyl) phosphate (TEHP) Phosphoric acid, tris(2-ethylhexyl) ester None Does not meet None planned at this time
Alkyl organophosphate 78-51-3 Tris(2-butoxethyl) phosphate (TBOEP) ethanol, 2-butoxy-, phosphate (3:1) HTML HTML None Meets one or more of the criteria Refer to risk management scope (updated human health component)
Alkyl organophosphate 298-07-7Table 1 Footnote b Bis(2-ethylhexyl) phosphate; bis (2-ethylhexyl) hydrogen phosphate (BEHP) Phosphoric acid, bis(2-ethylhexyl) ester None None None Does not meet None planned at this time
Aryl organophosphate 115-86-6Table 1 Footnote a Triphenyl phosphate (TPHP) Phosphoric acid, triphenyl ester HTML HTML HTML Meets one or more of the criteria Refer to risk management scopes
Aryl organophosphate 29761-21-5 Isodecyl diphenyl phosphate (IDDP) Phosphoric acid, isodecyl diphenyl ester None None HTML Meets one or more of the criteria Refer to risk management scope
Aryl organophosphate 56803-37-3 Tert-butylphenyl diphenyl phosphate (BPDP) Phosphoric acid, (1,1-dimethylethyl)phenyl diphenyl ester None None HTML Meets one or more of the criteria Refer to risk management scope
Aryl organophosphate 65652-41-7Table 1 Footnote a Bis(tert-butylphenyl) phenyl phosphate (BDMEPPP) Phosphoric acid, bis[(1,1-dimethylethyl)phenyl] phenyl ester None None HTML Meets one or more of the criteria Refer to risk management scope
Aryl organophosphate 68937-41-7Table 1 Footnote c Isopropylated triphenyl phosphate (IPPP) Phenol, isopropylated, phosphate (3:1) None None HTML Meets one or more of the criteria Refer to risk management scope
n/a 58965-66-5Table 1 Footnote a Tetradecabromo-1,4-diphenoxybenzene; perbromo-1,4-diphenoxybenzene (TDBDPB) Benzene, 1,2,4,5-tetrabromo-3,6-bis(pentabromophenoxy)- None None None Does not meet Under consideration
Table 1 Footnote a

This substance did not meet categorization criteria, but was included in this assessment because it was determined to be a priority as a result of the approach described for Identification of Risk Assessment Priorities.

Table 1 Return to footnote a referrer

Table 1 Footnote b

This CAS RN is a UVCB (unknown or variable composition, complex reaction products, or biological materials).

Table 1 Return to footnote b referrer

Table 1 Footnote c

This substance was not identified under subsection 73(1) of the Canadian Environmental Protection Act, 1999 (CEPA ), but was included in this assessment as it was considered a priority on the basis of other human health concerns.

Table 1 Return to footnote c referrer
Timelines
Date Activity
November 2025 Anticipated publication of the final assessment and proposed risk management approach.
November 22, 2025 Publication and start of 60-day public comment period on the Human Health Risk Characterization Document for the Assessment of Triphenyl phosphate (TPHP) and Tris(2-butoxyethyl) phosphate (TBOEP) and the Risk Management Scope For Triphenyl phosphate (TPHP) and Tris(2-butoxethyl) phosphate (TBOEP) (Updated Human Health Component). The related notice was published in the Canada Gazette, Part I: Vol. 161, No. 47.
June 24, 2023 Publication in Canada Gazette, Part I, of a notice under section 71 of CEPA.
November 6, 2021 Publication and start of 60-day public comment period on the Draft Screening Assessment for the Flame Retardants Group (including follow-up activities for TBOEP and TDBDPB) and the Risk Management Scope for TPHP, BPDP, BDMEPPP, IDDP, IPPP and TEP. The related notice was published in the Canada Gazette, Part I: Vol. 155, No. 45.

Human health risk characterization document

In November 21, 2025, the Human Health Risk Characterization Document for the Assessment of Triphenyl phosphate (TPHP) and Tris(2-butoxyethyl) phosphate (TBOEP) was published for a 60-day public comment period. The scope of the risk characterization document is limited to assessing potential human health concerns with respect to TPHP and TBOEP. Data identified or generated since the publication of the draft assessment are included. In addition to the proposed conclusions in the draft assessment, the Government is also proposing to conclude that TPHP and TBOEP may be harmful to human health at current levels of exposure.

A Risk Management Scope for TPHP and TBOEP (Updated Human Health Component) was also published for a 60-day public comment period. The scope outlines additional proposed risk management options for TPHP and TBOEP to address human health risks outlined in the risk characterization document. The risk management options described in the previously published scope remain under consideration.

Information gathering

Section 71 CMP 2023

In June 2023, a notice was published in the Canada Gazette, Part I: Vol. 157, No. 25 – June 24, 2023 under section 71 of CEPA. This notice applies to IPPP (CAS RN 68937-41-7) and TEP (CAS RN 78-40-0). More information is available on the Information gathering with respect to certain substances under the Chemicals Management Plan web page.

Background

Three other substances were identified as being a part of the Flame Retardants Group at the outset of the third phase of the CMP. These substances were subsequently determined to be of low concern to both human health and the environment, through a separate approach. The conclusions for CAS RNs 26446-73-1, 68527-01-5 and 68527-02-6 are provided in the Final Screening Assessment for the Rapid Screening of Substances with Limited General Population Exposure.

Page details

2025-11-21